English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Medullary thyroid cancer (MTC) is a neuroendocrine tumor that arises from the parafollicular Calcitonin-producing  C-cells of the thyroid. Typically the MTC is an extremely slow-growing cancer; however, it has a tendency of  spreading distant metastases fairly early. Systemic chemotherapy and external been radiotherapy have not  shown to give a good MTC response. As of date radical thyroidectomy is the main method of choice  for therapy. New compounds like tyrosine kinase inhibitors (TKIs) targeting signaling pathways may have a positive  outcome and be of great clinical benefits in patients with advanced and metastatic MTC. Somatostatin receptor are  over expressed in MTC and thus allows the use of radiolabeled somatostatin analogues for scintigraphic imaging before and after treatment for proper staging and follow-up of these patients. SPECT-CT is used to optimize  somatostatin-receptor scintigraphic protocols for MTC imaging. We have presented a case report of a patient who  underwent total thyroidectomy with bilateral lymphadenectomy in August 2006 due to the diagnosed MTC. This  patient was treated by chemotherapy and surgery during the period between January/2007- December/2014  because of the recurrent disease. In December 2014 the calcitonin level reached 56 000 pg/ml; whole body scan  with 740 MBq 99mTc-EDDA/HYNIC-TOC, followed by target SPECT-CT showed a total disease progression  with advanced metastatic dissemination into the body. The assigned therapy was with Caprelsa®(Vandetanib) 300  mg/d orally which was initialized from March 2015 until present. In June 2016 a control SPECT-CT somatostatinreceptor  scintigraphy with 740 MBq 99mTc-Tektrotyd was performed from which was reported a partial disease  response with a reduction of about 60% in size and a decrease in the number of metastatic lesions shown  to correlated with the decreased calcitonin level up to 1560 pg/ml. It can be concluded that SPECT-CT with 99mTc-  Tektrotyd has important clinical role for re-staging and follow-up of patients with recurrent and metastatic MTC after  target therapy.

SPECT-CT Modality for Imaging of Medullary Thyroid Cancer (MTC)